Compare Charles River Laboratories Intl. Inc (CRL) vs Endeavour Silver Corp (EXK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Endeavour Silver Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $287.33 (market cap $13.46B), while Endeavour Silver Corp trades at $10.59 (market cap $3.14B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 4.3× Endeavour Silver Corp's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals.
| CRL | EXK | |
|---|---|---|
Market Cap | $13.46B | $3.14B |
Sector | Health | Basic Materials |
52-Week High | $282.00 | $14.12 |
52-Week Low | $145.57 | $5.31 |
Enterprise Value | $16.30B | $3.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
Endeavour Silver (EXK) trades at $10.60, up 3.52% today, with strong technical momentum and bullish analyst sentiment. The company shows improving fundamentals with Q1 2026 earnings beating expectations and revenue growth projected from $468M in 2025 to $737M in 2026. Recent news highlights operational expansion, including the Terronera mine ramp-up and a new $25M credit facility, supporting future growth in silver and gold production.
Outlook is positive with 78.6% analyst buy ratings and a $15.50 consensus price target offering 46% upside. Key risks include execution of mine expansions, commodity price volatility, and the company's transition to profitability after a 2025 net loss. The stock presents a growth opportunity if operational targets are met, though investors should monitor quarterly earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →
